Skip to ContentSkip to Navigation
Over onsFaculty of Science and EngineeringOnderzoekGRIPPharmacoTherapy, -Epidemiology & -Economics (PTEE)Publications

Publications 2014

Below our publications are listed using several headings. Scientific publications relate to original research, often published internationally, but also in the Dutch language. Professional publications are in Dutch and relate to reviews and expressions of opinions.

Scientific publication international
1

Alsaad N, Wilffert B, van Altena R, de Lange WC, van der Werf TS, Kosterink JG, Alffenaar JW. Potential antimicrobial agents for the treatment of multidrug-resistant tuberculosis. Eur Respir J 2014;43:884-97

2 Arbouw ME, Hoge HL, Meulenbelt J, Jansman FG.Increase of baclofen intoxications: risks involved and management. Neth J Med.2014;72(9):497-9

3

Bergmeijer TO, Janssen PW, Schipper JC, Qaderdan K, Ishak M, Ruitenbeek RS, Asselbergs FW, van 't Hof AW, Dewilde WJ, Spano F, Herrman JP, Kelder JC, Postma MJ, de Boer A, Deneer VH, ten Berg JM. CYP2C19 genotype-guided antiplatelet therapy in ST-segment elevation myocardial infarction patients-Rationale and design of the Patient Outcome after primary PCI (POPular) Genetics study. Am Heart J 2014;168(1):16,22.e1

4

Berm EJ, Brummel-Mulder E, Paardekooper J, Hak E, Wilffert B, Maring JG. Determination of venlafaxine and O-desmethylvenlafaxine in dried blood spots for TDM purposes, using LC-MS/MS. Anal Bioanal Chem 2014;406:2349-53

5

Bezemer KD, Smink BE, van Maanen R, Verschraagen M, de Gier JJ. Prevalence of medicinal drugs in suspected impaired drivers and a comparison with the use in the general Dutch population. Forensic Sci Int 2014;241:203-11

6 Bijlsma MJ. G-computation might be used to control for confounding when estimating the population-level impact of interventions through outcome distribution curves. J Clin Epidemiol. 2014 Nov;67(11):1286. doi: 10.1016/j.jclinepi.2014.06.005. Epub 2014 Jul 19
7

Bulajeva A, Labberton L, Leikola S, Pohjanoksa-Mantyla M, Geurts MM, de Gier JJ, Airaksinen M. Medication review practices in European countries. Res Social Adm Pharm 2014

8

Charlton RA, Neville AJ, Jordan S, Pierini A, Damase-Michel C, Klungsoyr K, Nybo Andersen AM, Hansen AV, Gini R, Bos JH, Puccini A, Hurault-Delarue C, Brooks CJ, de Jong-van den Berg LT, de Vries CS. Healthcare databases in Europe for studying medicine use and safety during pregnancy. Pharmacoepidemiol Drug Saf 2014

9 Charlton R, Jordan S, Pierini A, Garne E, Neville A, Hansen A, Gini R, Thayer D, Tingay K, Puccini A, Bos H, Nybo Andersen A, Sinclair M, Dolk H, de Jong-van den Berg L. Selective serotonin reuptake inhibitor prescribing before, during and after pregnancy: a population-based study in six European regions. BJOG. 2014 Oct 28. doi: 10.1111/1471-0528.13143. [Epub ahead of print]
10

Connolly MP, Kuyvenhoven JP, Postma MJ, Nielsen SK. Cost and quality-adjusted life year differences in the treatment of active ulcerative colitis using once-daily 4g or twice-daily 2g mesalazine dosing. J Crohns Colitis 2014;8(5):357-62

11

Crijns I, Zomerdijk I, Sturkenboom M, de Jong-van den Berg L, Straus S. A comparison of pregnancy prevention programmes in Europe. Expert Opin Drug Saf 2014;13:411-20

12

Darvishian M, Gefenaite G, Turner RM, Pechlivanoglou P, Van der Hoek W, Van den Heuvel ER, Hak E. After adjusting for bias in meta-analysis seasonal influenza vaccine remains effective in community-dwelling elderly. J Clin Epidemiol. 2014 Jul;67(7):734-44. doi: 10.1016/j.jclinepi.2014.02.009. Epub 2014 Apr 24

13 Darvishian M, Bijlsma MJ, Hak E, van den Heuvel ER.Effectiveness of seasonal influenza vaccine in community-dwelling elderly people: a meta-analysis of test-negative design case-control studies. The Lancet. Infectious diseases 2014;14( 12):1228-39
14

Daud AN, Bergman JE, Bakker MK, Wang H, de Walle HE, Plosch T, Wilffert B. Pharmacogenetics of drug-induced birth defects: the role of polymorphisms of placental transporter proteins. Pharmacogenomics 2014;15(7):1029-41

15 de Boer PT, Wilschut JC, Postma MJ.Cost-effectiveness of vaccination against herpes zoster. Human vaccines & immunotherapeutics 2014;10(7):2048-61
16

De Cao E, Melegaro A, Klok R, Postma M. Optimising assessments of the epidemiological impact in the Netherlands of paediatric immunisation with 13-valent pneumococcal conjugate vaccine using dynamic transmission modelling. PLoS One 2014;9:e89415

17 Deetman Petronella E, Bakker Stephan JL, Kwakernaak Arjan J, Navis Gerjan, Dullaart Robin PF, on behalf of the PREVEND Study Group (Postma MJ). The Relationship of the Anti-Oxidant Bilirubin with Free Thyroxine Is Modified by Insulin Resistance in Euthyroid Subjects. PLoS One 2014; 9(3): e90886.
18

de Jong J, Bos JH, de Vries TW, de Jong-van den Berg LT. Use of antibiotics in rural and urban regions in The Netherlands: an observational drug utilization study. BMC Public Health 2014;14:677,2458-14-677

19

de Jonge L, Bos HJ, van Langen IM, de Jong-van den Berg LT, Bakker MK. Antibiotics prescribed before, during and after pregnancy in the Netherlands: a drug utilization study. Pharmacoepidemiol Drug Saf 2014;23:60-8

20

de Vries FM, Denig P, Visser ST, Hak E, Postma MJ. Cost-effectiveness of statins for primary prevention in patients newly diagnosed with type 2 diabetes in the Netherlands. Value Health 2014;17:223-30

21 de Vries FM, Kolthof J, Postma MJ, Denig P, Hak E. Efficacy of standard and intensive statin treatment for the secondary prevention of cardiovascular and cerebrovascular events in diabetes patients: a meta-analysis. PLoS ONE 2014; 9(11):e111247
22

de Vries L, van Hunsel F, Cuppers-Maarschalkerweerd B, van Puijenbroek E, van Grootheest K. Adjuvanted A/H1N1 (2009) influenza vaccination during pregnancy: Description of a prospective cohort and spontaneously reported pregnancy-related adverse reactions in the Netherlands. Birth Defects Res A Clin Mol Teratol 2014;

23 Divajeva D, Marsh T, Logstrup S, Kestens M, Vemer P, Kriaucioniene V, Peresson S, O'Kelly S, Rito A, Webber L. Economics of chronic diseases protocol: cost-effectiveness modelling and the future burden of non-communicable disease in Europe. BMC Public Health 2014;14:456,2458-14-456
24

Emich B, van Dijk L, Monteiro SP, de Gier JJ. A study comparing the effectiveness of three warning labels on the package of driving-impairing medicines. Int J Clin Pharm. 2014 Sep 10.

25 Fortanier AC, Venekamp RP, Boonacker CW, Hak E, Schilder AG, Sanders EA, Damoiseaux RA. Pneumococcal conjugate vaccines for preventing otitis media. Cochrane Database Syst Rev 2014;4:CD001480
26

Fugel HJ, Nuijten M, Faulkner E. The application of economics concepts to stratified medicine-use of health economics data to support market access for stratified medicine interventions. J Med Econ 2014;17(5):305-11

27

Fugel HJ, Connolly M, Nuijten M. An economic assessment of embryo diagnostics (Dx) - the costs of introducing non-invasive embryo diagnostics into IVF standard treatment practices. BMC Health Serv Res. 2014 Oct 9;14(1):482

28 Gefenaite G, Rahamat-Langendoen J, Ambrozaitis A, Mickiene A, Jancoriene L, Kuliese M, Velyvyte D, Niesters H, Stolk RP, Zagminas K, Hak E. Seasonal influenza vaccine effectiveness against influenza in 2012-2013: a hospital-based case-control study in Lithuania. Vaccine 2014;32(7):857-63
29 Gefenaite G, Tacken M, Kolthof J, Mulder B, Korevaar JC, Stirbu-Wagner I, Bos J, Stolk RP, Hak E. Predictors of influenza in the adult population during seasonal and A(H1N1)pdm09 pandemic influenza periods. Epidemiol Infect 2014;142(5):950-4
30 Gefenaite G, Bijlsma M, Bos H, Hak E. Did introduction of pneumococcal vaccines in the Netherlands decrease the need for respiratory antibiotics in children? Analysis of 2002 to 2013 data. Euro Surveill 2014;19(44):20948
31

Geurts MM, Zuydgeest IA, Walser S, Kijlstra NB, Petkova V, de Gier JJ. The evaluation of patient self-completion concordance forms used in community pharmacy: a comparison of two European countries. Int J Pharm Pract 2014;22(3):186-92

32

Härmark LV, Huls HJ, de Gier JJ, van Grootheest AC. Non-response in a pharmacy and patient-based intensive monitoring system: a quantitative study on non-response bias and reasons for non-response. Int J Pharm Pract 2014;22:159-62

33

Huang Y, Zhou Q, Haaijer-Ruskamp FM, Postma MJ. Economic evaluations of angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers in type 2 diabetic nephropathy: a systematic review. Bmc Nephrology 2014;15:15

34 Ivanova SA, Geers LM, Al Hadithy AF, Pechlivanoglou P, Semke AV, Vyalova NM, Rudikov EV, Fedorenko OY, Wilffert B, Bokhan NA, Brouwers JR, Loonen AJ. Dehydroepiandrosterone sulphate as a putative protective factor against tardive dyskinesia. Prog Neuropsychopharmacol Biol Psychiatry 2014;50:172-77
35 Ivanova SA, Geers LM, Al Hadithy AF, Pechlivanoglou P, Semke AV, Vyalova NM, Fedorenko OY, Brouwers JRBJ, Wilffert B, Loonen AJM. Tardive dyskinesia, dehydroepiandrosterone sulfate and cytochrome P450c17a gene polymorphism in psychiatric inpatients. European Neuropsychopharmacology 2014;24,S2:486-7
36

Janssen F, Hak E. Modelling population-level drug use with demographic and geographic approaches and techniques. Advances in Pharmacoepidemiology & Drug Safety 2014; 3(3):2167

37

Joosten MM, Gansevoort RT, Mukamal KJ, Lambers Heerspink HJ, Geleijnse JM, Feskens EJ, Navis G, Bakker SJ; PREVEND Study Group (Postma MJ). Sodium excretion and risk of developing coronary heart disease. Circulation. 2014 Mar 11;129(10):1121-8

38

Lako IM, Liemburg EJ, Van den Heuvel ER, Knegtering H, Bruggeman R, Taxis K. Estimating dopamine d2 receptor occupancy for doses of 8 antipsychotics: a meta-analysis: a reply. J Clin Psychopharmacol 2014;34(4):532-3

39

Lako IM, Wigman JT, Klaassen RM, Slooff CJ, Taxis K, Bartels-Velthuis AA; GROUP investigators. Psychometric properties of the self-report version of the Quick Inventory of Depressive Symptoms (QIDS-SR₁₆) questionnaire in patients with schizophrenia. BMC Psychiatry. 2014 Sep 3;14:247. doi: 10.1186/s12888-014-0247-2.

40

Le HH, Hodgkins P, Postma MJ, Kahle J, Sikirica V, Setyawan J, Erder MH, Doshi JA. Economic impact of childhood/adolescent ADHD in a European setting: the Netherlands as a reference case. Eur Child Adolesc Psychiatry 2014;23(7):587-98

41

Le HH, Connolly MP, Bahamondes L, Cecatti JG, Yu J, Hu HX. The burden of unintended pregnancies in Brazil: a social and public health system cost analysis. Int J Womens Health. 2014 Jul 16;6:663-70

42

Loonen AJ. No news without new scientific ideas. CNS Spectr 2014;19:110-1

43

Loonen AJ. Reply comment Prakash and Mandal. Acta Psychiatr Scand 2014;129:237

44

Mafirakureva N, Khoza S, Mvere DA, Chitiyo ME, Postma MJ, Van Hulst M. Incidence and pattern of 12 years of reported transfusion adverse events in Zimbabwe: a retrospective analysis. Blood Transfus 2014;12(3):362-7

45

Moolenaar LM, Connolly M, Huisman B, Postma MJ, Hompes PGA, van der Veen F, Mol BWJ. Costs and benefits of individuals conceived after IVF: a net tax evaluation in The Netherlands. Reproductive Biomedicine Online 2014;28:239-45

46

Mulder B, Schuiling-Veninga CCM, Bos HJ, De Vries TW, Jick SS, Hak E. Prenatal exposure to acid-suppressive drugs and the risk of allergic diseases in the offspring: a cohort study. Clinical and Experimental Allergy 2014;44:261-69

47

Mulder B, Schuiling-Veninga CC, Bos HJ, De Vries TW, Jick SS, Hak E. Response to the comment on: prenatal exposure to acid-suppressive drugs and the risk of allergic disease in the offspring: a cohort study. Clin Exp Allergy 2014;44(7):1005

48

Nguyen HT, Nguyen TD, Haaijer-Ruskamp FM, Taxis K. Errors in preparation and administration of insulin in two urban Vietnamese hospitals: an observational study. Nurs Res 2014;63:68-72

49 Nguyen HT, Pham HT, Vo DK, Nguyen TD, van den Heuvel ER, Haaijer-Ruskamp FM, Taxis K. The effect of a clinical pharmacist-led training programme on intravenous medication errors: a controlled before and after study. BMJ Qual Saf 2014;23:319-24
50 Nguyen TP, Nguyen TB, Nguyen TT, Vinh Hac V, Le HH, Schuiling-Veninga C, Postma MJ. Direct costs of hypertensive patients admitted to hospital in Vietnam- a bottom-up micro-costing analysis. BMC Health Serv Res. 2014 Oct 28;14:514. doi: 10.1186/s12913-014-0514-4
51

Thi Phuong Lan Nguyen, CCM Schuiling-Veninga, Thi Bach Yen Nguyen, Vu Thi Thu Hang, E. Pamela Wright, M.J. Postma. Models to Predict the Burden of Cardiovascular Disease Risk in a Rural Mountainous Region of Vietnam. Value in Health Regional Issues 2014;3 : 87–93

52

Ottenbros S, Teichert M, de Groot R, Griens F, Sodihardjo F, Wensing M, de Gier JJ. Pharmacist-led intervention study to improve drug therapy in asthma and COPD patients. Int J Clin Pharm 2014;36(2):336-44

53

Parouty MB, Le HH, Krooshof D, Postma MJ. Differential time preferences for money and quality of life. Pharmacoeconomics 2014;32:411-19

54

Parouty MBY, Postma MJ. A Probabilistic Theory for Intertemporal Indifference. Theoretical Economics Letters Vol.4 No.6, June 16, 2014:415-24   DOI: 10.4236/tel.2014.46053

55 Pechlivanoglou P, Le HH, Daenen S, Snowden JA, Postma MJ. Mixed treatment comparison of prophylaxis against invasive fungal infections in neutropenic patients receiving therapy for haematological malignancies: a systematic review. J Antimicrob Chemother 2014;69:1-11
56

Pechlivanoglou P, Wieringa JE, de Jager T, Postma MJ. The Effect of Financial and Educational Incentives on Rational Prescribing. a State-Space Approach. Health Econ 2014;

57

Pitman JP, Bocking A, Wilkinson R, Postma MJ, Basavaraju SV, von Finckenstein B, Mataranyika M, Marfin AA, Lowrance DW, Smit Sibinga CTh. The impact of external donor support through the U.S. President's Emergency Plan for AIDS Relief on the cost of red cell concentrate in Namibia, 2004-2011. Blood Transfus 2014;DOI 10.2450/2014.0122-14

58

Poole CD, Connolly MP, Chang J, Currie CJ. Health utility of patients with advanced gastrointestinal stromal tumors (GIST) after failure of imatinib and sunitinib: findings from GRID, a randomized, double-blind, placebo-controlled phase III study of regorafenib versus placebo. Gastric Cancer. 2014 Jun 24. [Epub ahead of print]

59 Pouwels KB, Bos JH, Hak E. ACE Inhibitors and Urinary Tract Infections. Epidemiology 2014;25(3):466-7
60 Pouwels KB and Hak E. Re: "a prospective study of statin drug use and lower urinary tract symptoms in older men". Am J Epidemiol 2014;179(7):927
61

Pouwels KB, Kalkman GA, Schagen D, Visser ST, Hak E. Is combined use of SSRIs and NSAIDs associated with an increased risk of starting peptic ulcer treatment? Br J Clin Pharmacol 2014;78(1):192-3

62

Radke PW, Halvorsen S, Jukema JW, Kolh P, Annemans L, Postma MJ, Ardissino D, Kristensen SD, Bassand JP, Collet JP, Morais J, Tunon J, Halcox J. Networks for improving care in patients with acute coronary syndrome: A framework. Acute Card Care 2014

63 Roessler R, Smallwood SA, Veenvliet JV, Pechlivanoglou P, Peng SP, Chakrabarty K, Groot-Koerkamp MJ, Pasterkamp RJ, Wesseling E, Kelsey G, Boddeke E, Smidt MP, Copray S. Detailed analysis of the genetic and epigenetic signatures of iPSC-derived mesodiencephalic dopaminergic neurons. Stem Cell Reports 2014;3;2(4):520-33. doi: 10.1016/j.stemcr.2014.03.001. eCollection 2014.
64

Rolfes L, van Hunsel F, Wilkes S, Grootheest KV, Puijenbroek EV. Adverse drug reaction reports of patients and healthcare professionals-differences in reported information. Pharmacoepidemiol Drug Saf 2014;

65

Rolfes L, Wilkes S, van Hunsel F, van Puijenbroek E, van Grootheest K. Important information regarding reporting of adverse drug reactions: a qualitative study. Int J Pharm Pract 2014;22(3):231-3

66 Schlander M, Garattini S, Holm S, Kolominsky-Rabas P, Nord E, Persson U, Postma MJ, Richardson J, Simoens S, de Sola Morales O, Tolley K, Toumi M. Incremental cost per quality-adjusted life year gained? The need for alternative methods to evaluate medical interventions for ultra-rare disorders. Journal of comparative effectiveness research 2014;3(4):399-422
67

Scheven L, Joosten MM, de Jong PE, Bakker SJ, Gansevoort RT; PREVEND study group (Postma MJ). The association of albuminuria with tubular reabsorption of uric acid: results from a general population cohort. J Am Heart Assoc. 2014;3(2):e000613

68 Setiawan D, Luttjeboer J, Westra TA, Wilschut JC, Suwantika AA, Daemen T, Atthobari J, Wilffert B, Postma MJ. The cost-effectiveness of HPV vaccination in addition to screening: a Dutch perspective. Expert review of vaccines 2014:1-16
69 Smit R, Postma MJ. Review of tick-borne encephalitis and vaccines: clinical and economical aspects. Expert Rev Vaccines 2014;:1-11
70

Standaert BA, Curran D, Postma MJ. Budget constraint and vaccine dosing: a mathematical modelling exercise. Cost Eff Resour Alloc 2014;12(1):3,7547-12-3

71

Standaert B, Ethgen O, Emerson R, Postma M, Mauskopf J. Comparing Cost-Effectiveness Results for a Vaccine Across Different Countries Worldwide: What Can We Learn? Adv Ther. 2014 Oct 21. [Epub ahead of print]

72 Stevanović J, O'Prinsen AC, Verheggen BG, Schuiling-Veninga N, Postma MJ, Pechlivanoglou P. Economic evaluation of primary prevention of cardiovascular diseases in mild hypertension: a scenario analysis for the Netherlands. Clin Ther 2014;36(3):368,384.e5
73

Stevanović J, Pompen M, Le HH, Rozenbaum MH, Tieleman RG, Postma MJ. Economic evaluation of apixaban for the prevention of stroke in non-valvular atrial fibrillation in the Netherlands. PLoS One. 2014 Aug 5;9(8):e103974

74

Stuurman-Bieze AG, Hiddink EG, van Boven JF, Vegter S. Proactive pharmaceutical care interventions decrease patients' nonadherence to osteoporosis medication. Osteoporos Int 2014;

75

Suwantika AA, Zakiyah N, Lestari K, Postma MJ. Accelerating the introduction of rotavirus immunization in Indonesia. Expert Rev Vaccines 2014;13:463-72

76

Suwantika AA, Beutels P, Postma MJ. Cost-effectiveness of hepatitis A vaccination in Indonesia. Hum Vaccin Immunother 2014;10(8)

77

Suwantika AA, Postma MJ. Expanding access to non-traditional vaccines: a perspective from Indonesia. Expert Rev Vaccines. 2014 Aug 22:1-3

78

Terwisscha Van Scheltinga AGT, Berghuis P, Nienhuis HH, Timmer-Bosscha H, Pot L, Gaykema SBM, Lub-de Hooge MN, Kosterink JGW, de Vries EGE, Schroder CP. Visualising dual downregulation of insulin-like growth factor receptor-1 and vascular endothelial growth factor-A by heat shock protein 90 inhibition effect in triple negative breast cancer. European Journal of Cancer 2014;50(14):2508-16

79

Terwisscha Van Scheltinga AGT, Lub-de Hooge MN, Abiraj K, Schroder CP, Pot L, Bossenmaier B, Thomas M, Holzlwimmer G, Friess T, Kosterink JGW, de Vries L. ImmunoPET and biodistribution with human epidermal growth factor receptor 3 targeting antibody Zr-89-RG7116. Mabs 2014;6(4):1051-8

80 Terwisscha van Scheltinga AG, Lub-de Hooge MN, Hinner MJ, Verheijen RB, Allersdorfer A, Hülsmeyer M, Nagengast WB, Schröder CP, Kosterink JG, de Vries EG, Audoly L, Olwill SA. In Vivo Visualization of MET Tumor Expression and Anticalin Biodistribution with the MET-Specific Anticalin Zr-89-PRS-110 PET Tracer. Journal of Nuclear Medicine 2014; 55(4):665-71
81 van Boven JFM, Chavannes NH, van der Molen T, Rutten-van Molken MPMH, Postnna MJ, Vegter S. Clinical and economic impact of non-adherence in COPD: A systematic review. Respir Med 2014;108:103-13
82 van Boven JF, Novak A, Driessen MT, Boersma C, Boomsma MM, Postma MJ. Economic evaluation of ropinirole prolonged release for treatment of Parkinson's disease in the Netherlands. Drugs Aging 2014;31(3):193-201
83

van Boven JF, Stuurman-Bieze AG, Hiddink EG, Postma MJ, Vegter S. Medication monitoring and optimization: a targeted pharmacist program for effective and cost-effective improvement of chronic therapy adherence. J Manag Care Pharm 2014;20(8):786-92

84

van Boven JF, Tommelein E, Boussery K, Mehuys E, Vegter S, Brusselle GG, Rutten-van Molken MP, Postma MJ. Improving inhaler adherence in patients with Chronic Obstructive Pulmonary Disease: a cost-effectiveness analysis. Respir Res 2014;15:66,9921-15-66

85

van Boven JFM, Tommelein E, Boussery K, Mehuys E, Vegter S, Brusselle GGO, Rutten-van Mölken MPMH & Postma MJ. Optimalisation de la pharmacothérapie en pharmacie d'officine chez des patients atteints de Bronchopneumopathie Chronique Obstructive (BPCO): une analyse coût-efficacité. Sep-2014 In : Journal de pharmacie de Belgique. 3, p. 15-6 2 p.

86

van Boven JF, van Raaij JJ, van der Galiën R, Postma MJ, van der Molen T, Dekhuijzen PR, Vegter S. Impact of multiple-dose versus single-dose inhaler devices on COPD patients' persistence with long-acting β2-agonists: a dispensing database analysis. NPJ Prim Care Respir Med. 2014 Oct 2;24:14069. doi: 10.1038/npjpcrm.2014.69

87 van der Elst KC, Pereboom M, van den Heuvel ER, Kosterink JG, Schölvinck EH, Alffenaar JW.Insufficient fluconazole exposure in pediatric cancer patients and the need for therapeutic drug monitoring in critically ill children.Clin Infect Dis. 2014;59(11):1527-33. doi: 10.1093/cid/ciu657. Epub 2014 Aug 22
88

van der Elst KC, van Alst M, Lub-de Hooge MN, van Hateren K, Kosterink JG, Alffenaar JW, Schölvinck EH. Clinical validation of the analysis of fluconazole in oral fluid in hospitalized children. Antimicrob Agents Chemother. 2014 Nov;58(11):6742-6. doi: 10.1128/AAC.03636-14. Epub 2014 Sep 2.

89

van der Meer DH, Wieringa A, Wegner I, Wilffert B, Ter Horst PG. Lactation studies of anticonvulsants: A quality review. Br J Clin Pharmacol. 2014 Oct 7. doi: 10.1111/bcp.12524. [Epub ahead of print]

90 Van der Velde RY, Brouwers JRBJ, Geusens P, Lems WF, Van den Berg PW.Calcium and vitamine D supplementation: state of art for daily practice. Food & Nutrition Res 2014; epub 7 August 2014
91

van Gelder MM, Bos JH, Roeleveld N, de Jong-van den Berg LT. Drugs associated with teratogenic mechanisms. Part I: dispensing rates among pregnant women in the Netherlands, 1998-2009. Hum Reprod 2014;29:161-7

92

van Gelder MM, de Jong-van den Berg LT, Roeleveld N. Drugs associated with teratogenic mechanisms. Part II : a literature review of the evidence on human risks. Hum Reprod 2014;29:168-83

93

van Gelder MM, van Rooij IA, de Jong-van den Berg LT, Roeleveld N. Teratogenic Mechanisms Associated with Prenatal Medication Exposure. Therapie 2014;69:13-24

94

van Hasselt FM, Coehorst Y, Verheijen-Breemhaar L, Feenstra B, Loonen AJ. Hidden diseases: tuberculosis in a woman with a severe mental illness. Tijdschr Psychiatr 2014;56(1):50-3

95

van Hasselt FM, Thier CS, van Rijswijk E, Loonen AJ. Is somatic health screening in patients with severe mental illness of added value? Perspect Psychiatr Care 2014;50(3):186-92

96 van Hasselt FM, Krabbe PF, Postma MJ, Loonen AJ.Evaluation of health promotion programmes in severe mental illness: theory and practice. Int J Methods Psychiatr Res. 2014 Dec 9. doi: 10.1002/mpr.1456. [Epub ahead of print]
97 van Hasselt FM, Oud MJ, Loonen AJ.Practical recommendations for improvement of the physical health care of patients with severe mental illness. Acta Psychiatr Scand. 2014 Dec 11. doi: 10.1111/acps.12372. [Epub ahead of print]
98

van Leeuwen RW, van Gelder T, Mathijssen RH, Jansman FG. Drug-drug interactions with tyrosine-kinase inhibitors: a clinical perspective. Lancet Oncol 2014;15(8):e315-26

99 van Leeuwen RW, van Gelder T, Mathijssen RH, Jansman FG. Drug interactions between tyrosine-kinase inhibitors and acid suppressive agents: more than meets the eye-Authors' reply. Lancet Oncol. 2014 Oct;15(11):e470-1. doi: 10.1016/S1470-2045(14)70459-0
100 van Leeuwen RW, van Gelder T, Mathijssen RH, Jansman FG. Drug interactions between tyrosine-kinase inhibitors and acid suppressive agents: more than meets the eye-Authors' reply. Lancet Oncol. 2014 Oct;15(11):e470-1. doi: 10.1016/S1470-2045(14)70459-0.
101 van Wanrooy MJP, Rodgers MGG, Uges DRA, Arends JP, Zijlstra JG, van der Werf TS, Kosterink JGW, Alffenaar JC. Low but Sufficient Anidulafungin Exposure in Critically Ill Patients. Antimicrob Agents Chemother 2014;58:304-8
102 van Wanrooy MJ, Span LF, Rodgers MG, van den Heuvel ER, Uges DR, van der Werf TS, Kosterink JG, Alffenaar JW.Inflammation is associated with voriconazole trough concentrations. Antimicrob Agents Chemother. 2014;58(12):7098-101. doi: 10.1128/AAC.03820-14. Epub 2014 Sep 15
103 van Wanrooy MJ, Proost JH, Rodgers MG, Zijlstra JG, Uges DR, Kosterink JG, van der Werf TS, Alffenaar JW.Limited-sampling strategies for anidulafungin in critically ill patients. Antimicrob Agents Chemother. 2014 Dec 8. pii: AAC.03375-14. [Epub ahead of print]
104

Vegter S, Oosterhof P, van Boven JF, Stuurman-Bieze AG, Hiddink EG, Postma MJ. Improving adherence to lipid-lowering therapy in a community pharmacy intervention program: a cost-effectiveness analysis. J Manag Care Pharm 2014;20(7):722-32

105

Vegter S, Tolley K. A network meta-analysis of the relative efficacy of treatments for actinic keratosis of the face or scalp in Europe. PLoS One. 2014 Jun 3;9(6):e96829

106

Vélez MP, Connolly MP, Kadoch IJ, Phillips S, Bissonnette F. Universal coverage of IVF pays off. Hum Reprod. 2014 Jun;29(6):1313-9

107

Vemer P and Postma MJ. A few years later: Update of the cost-effectiveness of infant pneumococcal vaccination in Dutch children. Hum Vaccin Immunother 2014;10(8)

108

Vermeulen KM, van Doormaal JE, Zaal RJ, Mol PGM, Lenderink AW, Haaijer-Ruskamp FM, Kosterink JGW, van den Bemt PMLA. Cost-effectiveness of an electronic medication ordering system (CPOE/CDSS) in hospitalized patients. International Journal of Medical Informatics 2014;83(8):572-80

109

Vu DH, Koster RA, Bolhuis MS, Greijdanus B, Altena RV, Nguyen DH, Brouwers J.R.B.J., Uges DRA, Alffenaar JW. Simultaneous determinationofrifampicin,clarithromycinandtheir metabolites indriedbloodspotsusingLC–MS/MS. Talanta 2014;121:9-17

110

Weersink RA, Taxis K, McGuire TM, van Driel ML. Consumers' questions about antipsychotic medication: revealing safety concerns and the silent voices of young men. Soc Psychiatry Psychiatr Epidemiol. 2014 Dec 30. [Epub ahead of print]

111

Wieringa A, Bethlehem C, Hoogendoorn M, van der Maten J, van Roon EN. Very late recovery of dapsone-induced methemoglobinemia. Clin Toxicol 2014;52:80-1

112

Wieringa A, Boslooper K, Hoogendoorn M, Joosten P, Beerden T, Storm H, Kibbelaar RE, Veldhuis GJ, van Kamp H, van Rees B, Kluin-Nelemans HC, Veeger NJ, van Roon EN. Comorbidity is an independent prognostic factor in patients with advanced-stage diffuse large B-cell lymphoma treated with R-CHOP: a population-based cohort study. Br J Haematol 2014;165(4):489-96

113

Wouters H, Quik EH, Boersma F, Nygård P, Bosman J, Böttger WM, Mulder H, Maring J-G, Wijma-Vos L, Beerden T, van Doormaal J, Postma MJ, Zuidema SU & Taxis K. Discontinuing Inappropriate Medication in Nursing Home Residents (DIM-NHR Study): protocol of a cluster randomised controlled trial. 2014 In : BMJ Open. 4, 10, p. e006082

114

Yska JP, van der Meer DH, Eilander W, Dreijer AR, Apers JA, Emous M, Totté ER, Wilffert B, van Roon EN. Influence of bariatric surgery on the use of some major drug classes. Naunyn-Schmiedeberg's Arch. Pharmacol 2014;387(1):S22

115

Zetstra-van der Woude PA, De Walle HE, Hoek A, Bos HJ, Boezen HM, Koppelman GH, de Jong-van den Berg LT, Scholtens S. Maternal high-dose folic acid during pregnancy and asthma medication in the offspring. Pharmacoepidemiol Drug Saf 2014;

Scientific publication national

1

Bijlsma MJ, Oortgiesen BE, Beernink RHJ, Bos HJ, Wilffert B, Hak E. Het effect van de CBG-waarschuwing op de trend in SSRI-gebruik in Nederland van 1998 tot 2010. Pharmaceutisch Weekblad Wetenschappelijk Platform 2014;8: A 1406:32-6

2 de Jong J, Bos HJ, de Vries TW, de Jong-van den Berg LTW. Antibioticagebruik bij kinderen en het gebruik van medicatie door de ouders, Pharmaceutisch Weekblad Wetenschappelijk Platform 2014;8:A 1412:38-42
3

Loonen AJM and Wilffert B. Regelgeving belemmert behandeling psychiatrische patiënt. Beter: functionele indicatie vermelden op het recept. Pharmaceutisch Weekblad Wetenschappelijk Platform 2014;april:22-4

4

van Boven JFM, Schuurman-Bieze AGG, Hiddink EG, Postma MJ, Vegter S. Gerichte farmaceutische zorg voor patiënten met astma en COPD: een oriënterende studie. Pharmaceutisch Weekblad Wetenschappelijk Platform 2014;8:A1413:49-53

5

Vollaard EJ, Kramers C, Brouwers JRBJ, Interactie NSAID’s en acetylsalicylzuur genegeerd Ned Tijdschr Geneeskunde 2014;158:A7893

6 Wilffert B. Alternatieve geneesmiddelen, een factor van belang bij chemotherapie. Pharmaceutisch Weekblad Wetenschappelijk Platform 2014;8:E1416:130
7

Wilffert B. Naar een duurzaam systeem voor geneesmiddelontwikkeling. Pharmaceutisch Weekblad Wetenschappelijk Platform 2014 ;8:E1419:152

8

Wilffert B. De apotheker, geneesmiddeldeskundige bij uitstek. Pharmaceutisch Weekblad Wetenschappelijk Platform 2014;8:e1427:173

Professional publication

1

Azim A, Wilffert B. Nut van genotypering CYP2D6 bij postmenopauzale borstkankerpatiënten behandeld met tamoxifen. MFM-Tijdschrift over praktijkgerichte farmacotherapie 2014;36-9

2

Brouwers JRBJ, Hemels MEW, Jansen PAF. Intensieve begeleiding bij doac’s en vka’s cruciaal, Pharmaceutisch weekblad 2014;149:22-4

3

Brouwers JRBJ, Bartels GL. Nieuwe inzichten verbeteren therapie bij hartfalen. Pharmaceutisch weekblad 2014;149(19 ):12-5

4

Brouwers JRBJ, Bartels GL. Innovaties in de farmacotherapie bij hartfalen. CardioActueel 2014;19(3) juni nr.

5 de Jong J. Antibioticagebruik bij kinderen; het kan minder, MFM-Tijdschrift over praktijkgerichte farmacotherapie 2014:47-52
6

Ekhart GC, van Puijenbroek EP. [Does sexual dysfunction persist upon discontinuation of selective serotonin reuptake inhibitors?]. Tijdschr Psychiatr. 2014;56(5):336-40. Dutch.

7

Anne Leendertse, Han de Gier, Dorien Zwart, Niek de Wit. Apotheker moet eerstelijns zorgverlener worden. Apotheker en huisarts onder één dak voorkomt veel medicatiefouten. Medisch Contact 11 december 2014:2514-15

8 Loonen A, van Panhuis P en Meester R. Belangrijke beperkingen van de gerechtelijke onderzoekmethode. Nederlands Juristenblad 2014;721:902-8
9

Loonen AJ, Van Oosten GJ. SSRI-substitutie riskant. Pharm Weekbl 2014;149(44):18

10

van Boven JFM, Schuurman-Bieze AGG, Hiddink EG, Postma MJ, Vegter S. Gerichte farmaceutische zorg voor patiënten met astma en COPD: een oriënterende studie. Pharmaceutisch weekblad 2014;8:A1413:49-53

11

van Boven J FM, Tommelein E, Boussery K, Mehuys E, Vegter S, Brusselle GGO, Rutten-van Mölken MPMH, Postma MJ.Het optimaliseren van de farmacotherapie bij patiënten met Chronisch Obstructief Longlijden (COPD) in de officina-apotheek: een kosten-effectiviteitsanalyse[1]. Farmaceutisch Tijdschrift 2014;94(3):15-6

12

van der Veen W, Cheung K-C. Soms hapert de interactie tussen mens en machine. Zorgverleners moeten letten op ‘nieuwe’ fouten door informatietechnologie. Pharm Weekbl 11 april 2014;149–15:22-4

13

van Hasselt FM. Lichamelijke gezondheid van patiënten met een ernstige psychische aandoening. Bijblijven 9-2014

14

van Hasselt FM, Coehorst Y, Verheijen-Breemhaar L, Feenstra B, Loonen AJ. Hidden diseases: tuberculosis in a woman with a severe mental illness. Tijdschr Psychiatr 2014;56(1):50-3

15

Van Leeuwen RWF, Van Gelder T, Mathijssen RHJ, Jansman FGA. Klinische relevantie van geneesmiddeleninteracties met tyrosinekinaseremmers. MFM-Tijdschrift over praktijkgerichte farmacotherapie 2014;4:21-6

16

Vegter S, Oosterhof P, van Boven JF, Stuurman-Bieze AG, Hiddink EG, Postma MJ. Therapietrouwbevordering lipidenverlagers is kosteneffectief. Pharmaceutisch weekblad 29 augustus 2014;149–35

Book (whole)
1

De Gier JJ, Borgsteede S. Commentaren Medicatiebewaking 2014/2015. Gier JJ de, Borgsteede S. (Hoofdredactie). Stichting Health Base: Houten, 2014

Book (chapter)

1

Frederix G, Vemer P. Decision analytic modelling: The need for disease specific model standardization. Dec-2014 research agenda for health economic evaluation: Health Economic Evidence Review December 2014. WORLD HEALTH ORGANIZATION

2

Postma MJ. Hoofdstuk 10: Kosten van de zorg wegen we af tegen langer en/of aangenamer leven. In: Gezonder Ouder Worden in Nederland. Volle Maan (ed.) NPN Drukkers: Breda, 2014:31-3

3 Postma MJ, Boersma C. Hoofdstuk 7: Farmaco-economie. In: Handboek Farmaceutische Geneeskunde. Out HJ, van Meurs P, van Olden R. (eds.) Bohn Stafleu van Loghum: Houten, 2014:99-118
4

Wilffert B, Swen JJ, Mulder H, van Schaik RHN, Nijenhuis M, Grandia L, Maitland-Van der Zee AH, Rongen GA, Schalekamp T, van der Weide J, de Boer A, Guchelaar H.-J, Touw DJ, Deneer VHM. Chapter 22. Implementation of Pharmacogenetics in Evidence-Based Medicine: Toward   Advancing Personalized Medicine. In: Handbook of personalized medicine. Advances in Nanotechnology, Drug Delivery, and Theory. Edited by Ioannis S. Vizirianakis. Pan Stanford Publishing, 2014: 953-1116

5

Heringa M, Gier JJ de. Contra-indicatie Verkeersdeelname. In: Commentaren Medicatiebewaking 2014/2015. Gier JJ de, Borgsteede S (Hoofdredactie). Stichting Health Base: Houten, 2014:1126-1144

Laatst gewijzigd:19 april 2016 09:34